Adage Capital Partners Gp, L.L.C. Kymera Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $2.54 Million - $7.66 Million	-180,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$35.3 - $64.68 $882,499 - $1.62 Million	-25,000 Reduced 12.2%	180,000 $7.62 Million
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $2.25 Million - $2.95 Million	-45,000 Reduced 18.0%	205,000 $13 Million
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $7.17 Million - $10 Million	150,000 Added 150.0%	250,000 $14.7 Million
Q4 2020 Feb 16, 2021	SELL	$28.07 - $87.83 $4.21 Million - $13.2 Million	-150,000 Reduced 60.0%	100,000 $6.2 Million
Q3 2020 Nov 16, 2020	BUY	$26.1 - $33.28 $6.53 Million - $8.32 Million	250,000 New	250,000 $8.08 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.22B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.